Ethical issues in establishing the efficacy and safety of long-acting injectable pre-exposure prophylaxis for HIV prevention: the HPTN 083 trial-Reference-Cited by-同舟云学术

Ethical issues in establishing the efficacy and safety of long-acting injectable pre-exposure prophylaxis for HIV prevention: the HPTN 083 trial

Published:2021-11 Issue:11 Volume:8 Page:e723-e728
ISSN:2352-3018
Container-title:The Lancet HIV
language:en
Short-container-title:The Lancet HIV

Author:

Sugarman Jeremy,Donnell Deborah J,Hanscom Brett,McCauley Marybeth,Grinsztejn Beatriz,Landovitz Raphael J

Funder

NIH

Publisher

Elsevier BV

Subject

Virology,Infectious Diseases,Immunology,Epidemiology

Reference17 articles.

1. Cabotegravir for HIV prevention in cisgender men and transgender women;Landovitz;N Engl J Med,2021

2. Delany-Moretlwe S, Hughes J, Bock P, et al. Long acting injectable cabotegravir is safe and effective in preventing HIV infection in cisgender women: interim results from HPTN 084. HIV R4P virtual conference; online; Jan 27, 2021 (abstr LB1479).

3. Why ethics guidance needs to be updated for contemporary HIV prevention research;Brown;J Int AIDS Soc,2020

4. Planning for HIV preexposure prophylaxis introduction: lessons learned from contraception;Delany-Moretlwe;Curr Opin HIV AIDS,2016

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Key stakeholders’ perspectives on providing oral pre-exposure prophylaxis as HIV-prevention standard of care in clinical trials in South Africa;African Journal of AIDS Research;2023-01-02

2. Testing for treatment effect twice using internal and external controls in clinical trials;Journal of Causal Inference;2023-01-01

3. Cabotegravir Extended-Release Injectable Suspension: A Review in HIV-1 Pre-Exposure Prophylaxis;Drugs;2022-09